Comparing Dalteparin and Enoxaparin for Preventing Blood Clots After Hip Surgery
Author Information
Author(s): Dranitsaris George, Jelincic Valentina, Choe Yoonhee
Primary Institution: Augmentium Pharma Consulting, Toronto, Canada and Eisai Inc., Woodcliff Lake, New Jersey, USA
Hypothesis
Is there a difference in safety and efficacy between dalteparin and enoxaparin for preventing venous thromboembolic events following total hip replacement surgery?
Conclusion
Dalteparin and enoxaparin are similarly effective and safe for preventing blood clots after hip surgery.
Supporting Evidence
- Both dalteparin and enoxaparin reduced the risk of venous thromboembolic events by 50% compared to placebo.
- There were no significant differences in major bleeding, heparin induced thrombocytopenia, or death between the two drugs.
- The study included a total of nine placebo-controlled trials.
- Statistical methods were used to indirectly compare the two drugs due to the lack of head-to-head trials.
Takeaway
This study looked at two medicines that help prevent blood clots after hip surgery and found they work about the same.
Methodology
A literature search was conducted for randomized trials evaluating dalteparin or enoxaparin prophylaxis in THR patients, followed by meta regression analysis.
Potential Biases
Potential biases associated with indirect comparisons and limited statistical power due to the number of trials.
Limitations
The analysis was indirect and not a true non-inferiority study, and some trials were not double-blinded.
Participant Demographics
Patients undergoing elective total hip replacement surgery, aged over 18.
Statistical Information
P-Value
p<0.001
Confidence Interval
(0.40 - 0.61)
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website